KR100591028B1 - 양성 전립선 과형성의 치료에 유용한 신규한 치환된 피리디노 아릴피페라진 및 이를 함유하는 약제학적 조성물 - Google Patents

양성 전립선 과형성의 치료에 유용한 신규한 치환된 피리디노 아릴피페라진 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR100591028B1
KR100591028B1 KR1020007009156A KR20007009156A KR100591028B1 KR 100591028 B1 KR100591028 B1 KR 100591028B1 KR 1020007009156 A KR1020007009156 A KR 1020007009156A KR 20007009156 A KR20007009156 A KR 20007009156A KR 100591028 B1 KR100591028 B1 KR 100591028B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
hydrogen
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007009156A
Other languages
English (en)
Korean (ko)
Other versions
KR20010041115A (ko
Inventor
구기-홍
머레이윌리암브이.
프로우티카테린피.
Original Assignee
오르토-맥네일 파마슈티칼, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오르토-맥네일 파마슈티칼, 인코퍼레이티드 filed Critical 오르토-맥네일 파마슈티칼, 인코퍼레이티드
Publication of KR20010041115A publication Critical patent/KR20010041115A/ko
Application granted granted Critical
Publication of KR100591028B1 publication Critical patent/KR100591028B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020007009156A 1998-02-20 1999-02-19 양성 전립선 과형성의 치료에 유용한 신규한 치환된 피리디노 아릴피페라진 및 이를 함유하는 약제학적 조성물 Expired - Fee Related KR100591028B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7532198P 1998-02-20 1998-02-20
US60/075,321 1998-02-20
PCT/US1999/003608 WO1999042448A1 (en) 1998-02-20 1999-02-19 Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
KR20010041115A KR20010041115A (ko) 2001-05-15
KR100591028B1 true KR100591028B1 (ko) 2006-06-22

Family

ID=22124955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007009156A Expired - Fee Related KR100591028B1 (ko) 1998-02-20 1999-02-19 양성 전립선 과형성의 치료에 유용한 신규한 치환된 피리디노 아릴피페라진 및 이를 함유하는 약제학적 조성물

Country Status (23)

Country Link
US (1) US6218396B1 (enExample)
EP (1) EP1054868B1 (enExample)
JP (1) JP2002503724A (enExample)
KR (1) KR100591028B1 (enExample)
CN (1) CN1121390C (enExample)
AR (1) AR014626A1 (enExample)
AT (1) ATE250580T1 (enExample)
AU (1) AU766398B2 (enExample)
BR (1) BR9909647A (enExample)
CZ (1) CZ294136B6 (enExample)
DE (1) DE69911582T2 (enExample)
DK (1) DK1054868T3 (enExample)
ES (1) ES2209468T3 (enExample)
HU (1) HUP0100781A3 (enExample)
IL (2) IL137954A0 (enExample)
NO (1) NO317103B1 (enExample)
NZ (1) NZ506462A (enExample)
PL (1) PL342339A1 (enExample)
PT (1) PT1054868E (enExample)
TR (1) TR200003220T2 (enExample)
TW (1) TW565555B (enExample)
WO (1) WO1999042448A1 (enExample)
ZA (1) ZA991315B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269807C (zh) * 1997-05-12 2006-08-16 奥索-麦克尼尔药品公司 可用于治疗良性前列腺肥大的芳基取代哌嗪
ES2282279T3 (es) 2000-08-08 2007-10-16 Ortho-Mcneil Pharmaceutical, Inc. No-imidazol ariloxipiperidina como ligandos del receptor h3.
JP3878178B2 (ja) * 2001-12-28 2007-02-07 武田薬品工業株式会社 排尿障害予防治療剤
USD545208S1 (en) 2006-09-27 2007-06-26 001 Corporation Perfume bottle and cap
EP2077262A4 (en) * 2006-10-23 2011-12-28 Takeda Pharmaceutical IMINOPYRIDINE DERIVATIVE AND USE THEREOF
MX2010011652A (es) * 2008-04-23 2010-12-06 Takeda Pharmaceutical Derivados de iminopiridina y uso de los mismos.
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
CN103980195A (zh) * 2014-04-28 2014-08-13 广州医科大学 酰胺类苯基哌嗪衍生物及其盐与在制备治疗良性前列腺增生症药物中的应用
CN108530391B (zh) * 2018-05-17 2022-05-17 袁牧 一种酰胺类芳基哌嗪衍生物及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
US5403847A (en) 1992-11-13 1995-04-04 Synaptic Pharmaceutical Corporation Use of α1C specific compounds to treat benign prostatic hyperlasia
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
US5688795A (en) * 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
AU8130298A (en) * 1997-07-15 1999-02-10 Sankyo Company Limited Piperazine derivatives

Also Published As

Publication number Publication date
JP2002503724A (ja) 2002-02-05
CN1121390C (zh) 2003-09-17
EP1054868A1 (en) 2000-11-29
AU766398B2 (en) 2003-10-16
IL137954A0 (en) 2001-10-31
DE69911582D1 (de) 2003-10-30
US6218396B1 (en) 2001-04-17
CZ20003044A3 (cs) 2001-04-11
NO20004141L (no) 2000-10-19
HUP0100781A2 (hu) 2001-08-28
ZA991315B (en) 2000-11-20
AR014626A1 (es) 2001-03-28
TW565555B (en) 2003-12-11
WO1999042448A1 (en) 1999-08-26
TR200003220T2 (tr) 2001-04-20
HK1030776A1 (en) 2001-05-18
CN1291188A (zh) 2001-04-11
IL137954A (en) 2007-06-03
DK1054868T3 (da) 2003-12-22
KR20010041115A (ko) 2001-05-15
NZ506462A (en) 2003-07-25
CZ294136B6 (cs) 2004-10-13
ES2209468T3 (es) 2004-06-16
BR9909647A (pt) 2000-11-21
ATE250580T1 (de) 2003-10-15
NO20004141D0 (no) 2000-08-18
AU3302599A (en) 1999-09-06
PL342339A1 (en) 2001-06-04
EP1054868B1 (en) 2003-09-24
HUP0100781A3 (en) 2002-12-28
DE69911582T2 (de) 2005-09-15
PT1054868E (pt) 2004-01-30
NO317103B1 (no) 2004-08-09

Similar Documents

Publication Publication Date Title
EP0470039B1 (en) Novel 3-arylindole and 3-arylindazole derivatives
KR100591028B1 (ko) 양성 전립선 과형성의 치료에 유용한 신규한 치환된 피리디노 아릴피페라진 및 이를 함유하는 약제학적 조성물
US6384035B1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia
US6780994B2 (en) Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
US6063785A (en) Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
US6362338B1 (en) Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
EP1346983A2 (en) Phthalimido arylpiperazines as alpha 1A receptor antagonists useful in the treatment of benign prostatic hyperplasia
HK1030776B (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
MXPA00008219A (en) Phtalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia
HK1031872B (en) Phtalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia
CZ20003045A3 (cs) Ftalimidoarylpiperaziny jako antagonisty alfa IA receptorů použitelné při léčení benigního zbytnění prostaty
MXPA00008220A (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20090609

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100613

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100613

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000